<p>Harbor Capital Advisors Inc. 在最近向美国证券交易委员会（SEC）提交的文件中表示，其在 MiMedx Group, Inc (NASDAQ:MDXG - 免费报告) 的持股在第三季度减少了 71.3%。该机构投资者在此期间出售了 833,432 股后，持有该公司 335,763 股股票。截至其最近的 SEC 文件，Harbor Capital Advisors Inc. 持有的 MiMedx Group 股票约占 0.23%，价值 2,344,000 美元。</p>
<p>其他几家对冲基金也最近调整了对该公司的持股。CWM LLC 在第二季度将其在 MiMedx Group 的持股增加了 63.8%。CWM LLC 目前持有该公司 4,857 股股票，价值 30,000 美元，此前在上个季度又增持了 1,892 股。Rhumbline Advisers 在第一季度将其在 MiMedx Group 的持股增加了 1.4%。Rhumbline Advisers 目前持有该公司 177,156 股股票，价值 1,346,000 美元，此前在上个季度又购买了 2,436 股。SkyView Investment Advisors LLC 在第二季度将其在 MiMedx Group 的持股增加了 3.6%。SkyView Investment Advisors LLC 目前持有该公司 87,734 股股票，价值 523,000 美元，此前在此期间又增持了 3,032 股。新泽西州警察和消防员退休系统在第二季度将其在 MiMedx Group 的持股增加了 14.9%。新泽西州警察和消防员退休系统目前持有该公司 28,135 股股票，价值 172,000 美元，此前在此期间又增持了 3,642 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 MiMedx Group 的持股增加了 5.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前持有该公司 73,518 股股票，价值 559,000 美元，此前在上个季度又增持了 4,049 股。机构投资者持有该公司 79.15% 的股票。</p>
<h2>MiMedx Group 的内部活动</h2>
<p>在相关消息中，内部人士 Kimberly Maersk-Moller 于 11 月 6 日星期四出售了 58,300 股该公司的股票。股票以平均价格 7.42 美元出售，总交易额为 432,586.00 美元。出售后，该内部人士直接持有该公司 236,982 股股票，价值约 1,758,406.44 美元。这代表其持股减少了 19.74%。该交易在向 SEC 提交的文件中披露，相关文件可通过此超链接访问。内部人士持有该公司 1.70% 的股票。</p>
<h2>MiMedx Group 股价上涨 1.1%</h2>
<p>MDXG 的股票在星期五开盘价为 7.08 美元。该公司的 50 日移动平均线为 7.05 美元，200 日移动平均线为 6.88 美元。MiMedx Group, Inc 的 52 周低点为 5.79 美元，52 周高点为 9.71 美元。该公司的市值为 10.5 亿美元，市盈率为 26.20，贝塔系数为 1.64。该公司的债务与股本比率为 0.07，速动比率为 3.95，流动比率为 4.41。</p>
<p>MiMedx Group (NASDAQ:MDXG - 获取免费报告) 最近于 11 月 13 日星期一发布了季度财报。该公司报告本季度每股收益为（0.03）美元。该公司的季度收入为 67.69 百万美元。MiMedx Group 的净利润率为 10.38%，股本回报率为 27.19%。作为一个整体，研究分析师预测 MiMedx Group, Inc 本年度将发布 0.3 的每股收益。</p>
<h2>分析师评级调整</h2>
<p>一些股票分析师最近对该股票进行了评估。华尔街 Zen 在 11 月 2 日星期日的报告中将 MiMedx Group 的股票评级从 “买入” 上调至 “强力买入”。瑞穗证券在 12 月 17 日的研究报告中将 MiMedx Group 的股票目标价从 12.00 美元下调至 10.00 美元，并对该股票给予 “跑赢大盘” 的评级。最后，Weiss Ratings 在周一的研究报告中重新发布了对 MiMedx Group 股票的 “持有（c）” 评级。两位投资分析师对该股票给予了买入评级，一位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 11.00 美元。</p>
<p><strong>获取我们关于 MDXG 的最新报告</strong></p>
<h2>MiMedx Group 公司简介</h2>
<p>（免费报告）</p>
<p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
<p>MiMedx 的主要产品包括以 EpiFix® 和 AmnioFix® 等名称品牌的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 MiMedx Group</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备开战</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>来自奇怪的新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
<p>在考虑 MiMedx Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 MiMedx Group 并不在名单上。</p>
<p>虽然 MiMedx Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXG

<p>Harbor Capital Advisors Inc. 在第三季度减少了对 MiMedx Group, Inc 的持股，降幅为 71.3%，目前持有 335,763 股。其他对冲基金也调整了他们的持股。MiMedx Group 的股票上涨 1.1%，市值为 10.5 亿美元。分析师对该股票给予了 “适度买入” 的共识评级，目标价格为 11.00 美元</p>

<p>Harbor Capital Advisors Inc. trimmed its position in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 71.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 335,763 shares of the company's stock after selling 833,432 shares during the period. Harbor Capital Advisors Inc. owned about 0.23% of MiMedx Group worth $2,344,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Harbor Capital Advisors Inc. 在最近向美国证券交易委员会（SEC）提交的文件中表示，其在 MiMedx Group, Inc (NASDAQ:MDXG - 免费报告) 的持股在第三季度减少了 71.3%。该机构投资者在此期间出售了 833,432 股后，持有该公司 335,763 股股票。截至其最近的 SEC 文件，Harbor Capital Advisors Inc. 持有的 MiMedx Group 股票约占 0.23%，价值 2,344,000 美元。</p>
</div><p>Several other hedge funds have also recently modified their holdings of the company. CWM LLC grew its holdings in shares of MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company's stock valued at $30,000 after acquiring an additional 1,892 shares in the last quarter. Rhumbline Advisers boosted its position in MiMedx Group by 1.4% in the first quarter. Rhumbline Advisers now owns 177,156 shares of the company's stock worth $1,346,000 after purchasing an additional 2,436 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company's stock valued at $523,000 after purchasing an additional 3,032 shares during the period. Police &amp; Firemen s Retirement System of New Jersey grew its stake in MiMedx Group by 14.9% in the 2nd quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 28,135 shares of the company's stock valued at $172,000 after purchasing an additional 3,642 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company's stock valued at $559,000 after purchasing an additional 4,049 shares during the last quarter. Institutional investors own 79.15% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金也最近调整了对该公司的持股。CWM LLC 在第二季度将其在 MiMedx Group 的持股增加了 63.8%。CWM LLC 目前持有该公司 4,857 股股票，价值 30,000 美元，此前在上个季度又增持了 1,892 股。Rhumbline Advisers 在第一季度将其在 MiMedx Group 的持股增加了 1.4%。Rhumbline Advisers 目前持有该公司 177,156 股股票，价值 1,346,000 美元，此前在上个季度又购买了 2,436 股。SkyView Investment Advisors LLC 在第二季度将其在 MiMedx Group 的持股增加了 3.6%。SkyView Investment Advisors LLC 目前持有该公司 87,734 股股票，价值 523,000 美元，此前在此期间又增持了 3,032 股。新泽西州警察和消防员退休系统在第二季度将其在 MiMedx Group 的持股增加了 14.9%。新泽西州警察和消防员退休系统目前持有该公司 28,135 股股票，价值 172,000 美元，此前在此期间又增持了 3,642 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 MiMedx Group 的持股增加了 5.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前持有该公司 73,518 股股票，价值 559,000 美元，此前在上个季度又增持了 4,049 股。机构投资者持有该公司 79.15% 的股票。</p>
</div><h2>Insider Activity at MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 的内部活动</h2>
</div><p>In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the company's stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the sale, the insider directly owned 236,982 shares in the company, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.70% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Kimberly Maersk-Moller 于 11 月 6 日星期四出售了 58,300 股该公司的股票。股票以平均价格 7.42 美元出售，总交易额为 432,586.00 美元。出售后，该内部人士直接持有该公司 236,982 股股票，价值约 1,758,406.44 美元。这代表其持股减少了 19.74%。该交易在向 SEC 提交的文件中披露，相关文件可通过此超链接访问。内部人士持有该公司 1.70% 的股票。</p>
</div><h2>MiMedx Group Trading Up 1.1%</h2>
<div class="lb-trans"><h2>MiMedx Group 股价上涨 1.1%</h2>
</div><p>Shares of MDXG opened at $7.08 on Friday. The business has a 50-day moving average of $7.05 and a 200 day moving average of $6.88. MiMedx Group, Inc has a fifty-two week low of $5.79 and a fifty-two week high of $9.71. The firm has a market cap of $1.05 billion, a P/E ratio of 26.20 and a beta of 1.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.</p>
<div class="lb-trans"><p>MDXG 的股票在星期五开盘价为 7.08 美元。该公司的 50 日移动平均线为 7.05 美元，200 日移动平均线为 6.88 美元。MiMedx Group, Inc 的 52 周低点为 5.79 美元，52 周高点为 9.71 美元。该公司的市值为 10.5 亿美元，市盈率为 26.20，贝塔系数为 1.64。该公司的债务与股本比率为 0.07，速动比率为 3.95，流动比率为 4.41。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.03) EPS for the quarter. The business had revenue of $67.69 million for the quarter. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. As a group, research analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current year.</p>
<div class="lb-trans"><p>MiMedx Group (NASDAQ:MDXG - 获取免费报告) 最近于 11 月 13 日星期一发布了季度财报。该公司报告本季度每股收益为（0.03）美元。该公司的季度收入为 67.69 百万美元。MiMedx Group 的净利润率为 10.38%，股本回报率为 27.19%。作为一个整体，研究分析师预测 MiMedx Group, Inc 本年度将发布 0.3 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of MiMedx Group from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Sunday, November 2nd. Mizuho lowered their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of MiMedx Group in a research report on Monday. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $11.00.</p>
<div class="lb-trans"><p>一些股票分析师最近对该股票进行了评估。华尔街 Zen 在 11 月 2 日星期日的报告中将 MiMedx Group 的股票评级从 “买入” 上调至 “强力买入”。瑞穗证券在 12 月 17 日的研究报告中将 MiMedx Group 的股票目标价从 12.00 美元下调至 10.00 美元，并对该股票给予 “跑赢大盘” 的评级。最后，Weiss Ratings 在周一的研究报告中重新发布了对 MiMedx Group 股票的 “持有（c）” 评级。两位投资分析师对该股票给予了买入评级，一位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 11.00 美元。</p>
</div><p><strong>Get Our Latest Report on MDXG</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 MDXG 的最新报告</strong></p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要产品包括以 EpiFix® 和 AmnioFix® 等名称品牌的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MiMedx Group</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备开战</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>来自奇怪的新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MiMedx Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 MiMedx Group 并不在名单上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MiMedx Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Harbor Capital Advisors Inc. 减少了其在 MiMedx Group, Inc $MDXG 中的持股